vs
Side-by-side financial comparison of A2Z CUST2MATE SOLUTIONS CORP. (AZ) and Mind Medicine (MindMed) Inc. (DFTX). Click either name above to swap in a different company.
A2Z CUST2MATE SOLUTIONS CORP. is the larger business by last-quarter revenue ($1.5M vs $906.0K, roughly 1.7× Mind Medicine (MindMed) Inc.). A2Z CUST2MATE SOLUTIONS CORP. runs the higher net margin — -90.4% vs -2634.0%, a 2543.6% gap on every dollar of revenue. On growth, A2Z CUST2MATE SOLUTIONS CORP. posted the faster year-over-year revenue change (-1.6% vs -16.1%).
Definium Therapeutics, Inc., formerly known as MindMed, is a New York-based biotechnology company that is currently developing clinical and therapeutic applications for psychedelic and, more broadly, psychoplastogenic drugs.
AZ vs DFTX — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2023
| Metric | | |
|---|---|---|
| Revenue | $1.5M | $906.0K |
| Net Profit | $-1.4M | $-23.9M |
| Gross Margin | 34.0% | — |
| Operating Margin | -265.9% | -2450.8% |
| Net Margin | -90.4% | -2634.0% |
| Revenue YoY | -1.6% | -16.1% |
| Net Profit YoY | 60.4% | -386.7% |
| EPS (diluted) | — | $-0.58 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | $1.5M | — | ||
| Q2 25 | $1.2M | — | ||
| Q1 25 | $2.0M | — | ||
| Q3 24 | $1.6M | — | ||
| Q2 24 | $1.1M | — | ||
| Q4 23 | — | $906.0K | ||
| Q3 23 | — | $1.2M | ||
| Q2 23 | — | $1.3M |
| Q3 25 | $-1.4M | — | ||
| Q2 25 | $-12.6M | — | ||
| Q1 25 | $-6.8M | — | ||
| Q3 24 | $-3.5M | — | ||
| Q2 24 | $-3.2M | — | ||
| Q4 23 | — | $-23.9M | ||
| Q3 23 | — | $-17.9M | ||
| Q2 23 | — | $-29.1M |
| Q3 25 | 34.0% | — | ||
| Q2 25 | 23.3% | — | ||
| Q1 25 | 31.7% | — | ||
| Q3 24 | 43.9% | — | ||
| Q2 24 | 7.4% | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
| Q3 25 | -265.9% | — | ||
| Q2 25 | -585.9% | — | ||
| Q1 25 | -381.4% | — | ||
| Q3 24 | -167.0% | — | ||
| Q2 24 | -272.1% | — | ||
| Q4 23 | — | -2450.8% | ||
| Q3 23 | — | -1858.6% | ||
| Q2 23 | — | -2226.1% |
| Q3 25 | -90.4% | — | ||
| Q2 25 | -1085.4% | — | ||
| Q1 25 | -342.1% | — | ||
| Q3 24 | -224.7% | — | ||
| Q2 24 | -277.4% | — | ||
| Q4 23 | — | -2634.0% | ||
| Q3 23 | — | -1541.1% | ||
| Q2 23 | — | -2222.0% |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | $-0.19 | — | ||
| Q3 24 | $-0.15 | — | ||
| Q2 24 | $-0.05 | — | ||
| Q4 23 | — | $-0.58 | ||
| Q3 23 | — | $-0.45 | ||
| Q2 23 | — | $-0.76 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $43.2M | $99.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $71.3M | $78.1M |
| Total Assets | $81.9M | $124.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $43.2M | — | ||
| Q2 25 | $28.5M | — | ||
| Q1 25 | $24.2M | — | ||
| Q3 24 | $3.4M | — | ||
| Q2 24 | $653.0K | — | ||
| Q4 23 | — | $99.7M | ||
| Q3 23 | — | $117.7M | ||
| Q2 23 | — | $116.9M |
| Q3 25 | $71.3M | — | ||
| Q2 25 | $31.5M | — | ||
| Q1 25 | $31.3M | — | ||
| Q3 24 | $-504.0K | — | ||
| Q2 24 | $-340.0K | — | ||
| Q4 23 | — | $78.1M | ||
| Q3 23 | — | $96.0M | ||
| Q2 23 | — | $106.0M |
| Q3 25 | $81.9M | — | ||
| Q2 25 | $46.1M | — | ||
| Q1 25 | $42.2M | — | ||
| Q3 24 | $10.2M | — | ||
| Q2 24 | $7.2M | — | ||
| Q4 23 | — | $124.5M | ||
| Q3 23 | — | $141.6M | ||
| Q2 23 | — | $142.1M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-4.0M | $-20.6M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $-4.0M | — | ||
| Q2 25 | $-5.9M | — | ||
| Q1 25 | $-3.8M | — | ||
| Q3 24 | $-658.0K | — | ||
| Q2 24 | $-3.7M | — | ||
| Q4 23 | — | $-20.6M | ||
| Q3 23 | — | $-16.6M | ||
| Q2 23 | — | $-13.8M |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
